CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Allogene Therapeutics Reports Q3 2026 Net Loss of $50.4 Million

By Public Technologies
  • Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million.
  • Cash, cash equivalents and investments totaled $388.9 million at September 30, supporting a projected cash runway into 2029.
  • The next ALPHA3 clinical update is expected in mid-2027, with trial enrollment completion anticipated by year-end 2027.
  • Updated ALLO-329 autoimmune disease trial results are scheduled for presentation November 9, 2026.
  • Projected 2026 GAAP operating expenses total approximately $225 million, including about $35 million in non-cash stock-based compensation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051602PRIMZONEFULLFEED9870831) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk